The interactive session, co-hosted by Zacks Small Cap Research, begins at 10:30 am ET and allows investors to engage directly with company leadership. MetaVia is positioning its candidate DA-1726 as a potential successor to existing GLP-1 therapies, citing its dual agonist mechanism that targets both GLP1R and GCGR receptors to simultaneously suppress appetite and boost energy expenditure. Phase 1 trial data for the compound suggests significant outcomes in weight loss and glucose regulation.

Beyond obesity, the company is advancing vanoglipel, a first-in-class candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH). Recent Phase 2a clinical results indicate the drug provides direct hepatic benefits—including reductions in inflammation and fibrosis—that operate independently of broader metabolic improvements. Investors interested in deeper analysis can schedule one-on-one meetings with management through the conference portal or by contacting company representatives directly.